A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies

Kelly M Jones,1 Shivanthi Balalla,1 Alice Theadom,1 Gordon Jackman,2 Valery L Feigin1

ABSTRACT

Background Accurate prevalence figures estimating the number of survivors of poliomyelitis (disease causing acute flaccid paralysis) following poliovirus infection are not available. We aim to undertake a systematic review of all literature concerning the prevalence of survivors of poliomyelitis.

Methods Electronic databases were searched from 1900 up to May 2016 for peer-reviewed studies using a population-based approach with a defined denominator and some form of diagnostic or clinical verification of polio. Exclusion criteria were any prevalence data that were unable to be extracted or calculated and studies reporting on incidence only. The quality of each included study was assessed using an existing tool modified for use in prevalence studies. Average crude prevalence rates were used to calculate worldwide estimates.

Results Thirty-one studies met criteria with 90% of studies conducted in low-income to lower middle-income countries. Significant variability in the prevalence of survivors of poliomyelitis was revealed, in low-income to lower middle-income (15 per 100 000 in Nigeria to 1733 per 100 000 in India) and upper-middle to high-income countries (24 (Japan) to 380 per 100 000 (Brazil)).

The total combined prevalence of survivors of poliomyelitis for those studies at low to moderate risk of bias ranged from 165 (high-income countries) to 425 (low-income to lower middle-income countries) per 100 000 person-years.

Conclusions These results highlight the need for future epidemiological studies of poliomyelitis to examine nationally representative samples, including all ages and greater focus on high-income countries. Such efforts will improve capacity to provide reliable and more robust worldwide prevalence estimates.

INTRODUCTION

Poliomyelitis (polio) is a highly infectious, incurable viral disease caused by a wild or live vaccine-derived virus that remains endemic in Afghanistan, Pakistan and Nigeria.1 Since the creation of the Global Polio Eradication Initiative in 1988, alongside mass vaccination programmes aimed at eradicating polio, the number of new cases has been cut by 99%2 from 350 000 cases to 74 reported cases in 2015.3 Polio, a human enterovirus,4 primarily affects children aged <5 years with infection most commonly spread by the fecal–oral route. Up to 75% of poliovirus infections in children are asymptomatic, while approximately 24% of cases may experience a low-grade fever and sore throat.5 Less than 1% of cases experience viral replication in the central nervous system causing temporary or permanent acute flaccid paralysis (AFP) (known as poliomyelitis).6 While there is wide variability regarding the impact of poliovirus infection, estimates suggest that 12–20 million individuals are living with the consequences of the disease worldwide.7 Up to 40% of all survivors of acute poliomyelitis will experience postpoliomyelitis syndrome (PPS),8 being the delayed appearance of new or worsening disabling neuromuscular symptoms 30–40 years after the original poliomyelitis attack. However, recent accurate prevalence rates estimating the number of survivors of poliomyelitis are not available.

Published international prevalence studies are problematic. These studies have (1) tended to focus on the initial disease and needs in the immediate aftermath, (2) been inconsistent in the definition of 'polio survivor,' with it often unclear whether this...
refers all those infected or only those sustaining some form of residual disability, (3) predominantly focused on health status rather than the everyday effects on people’s lives, their needs and those of their carers, (4) produced inconsistent findings on long-term outcomes, perhaps due to cultural differences, and/or have been (5) limited to lameness surveys of children in mostly low-income to lower middle-income countries. Hence, regional prevalence estimates are often crude and fragmentary. This systematic literature review aims to synthesise current knowledge on the prevalence of survivors of poliomyelitis worldwide using all available population-based polio prevalence studies.

METHODS

This review is reported according to the PRISMA Statement.

Search strategy

We searched MEDLINE (1946–May 2016), CINAHL (1937–May 2016), Psychology and Behavioral Sciences Collection (1945–May 2016), ProQuest (1971–May 2016), Scopus (1970–May 2016) and Web of Science (1900–May 2016) databases from inception to May 2016 for relevant studies. A search strategy was developed for Medline using ‘post-polio syndrome’, ‘poliovirus’, ‘polio’, ‘post-polio’, ‘poliomyelitis’, ‘postpoliomyelitis’, ‘PPMA’, ‘PPMD’, ‘LEOP’, or ‘late effects of polio’ and ‘epidemiol’, ‘rate’, ‘proportion’, or ‘prevalence*’, and was then repeated for other database searches. The complete search strategy is available online (see online supplementary table S1). Hand searching of included articles was also undertaken.

Inclusion/exclusion criteria

Inclusion criteria were: peer reviewed; written in English; reporting of prevalence of poliomyelitis survivors; use of a population-based, epidemiology approach with a defined denominator; and some form of diagnostic or clinical verification of polio. Only those studies reporting on cases ascertained from a general population sample (ie, not restricted by gender or ethnicity) were included to enable comparison between populations and with other conditions, and to enhance representativeness of the findings. Studies in which any prevalence data were unable to be extracted or calculated, or studies reporting incidence data only, were excluded. Duplicate publications reporting on the same research data were also removed.

Quality appraisal

Each study was assessed for methodological quality and risk of bias using a 10-item assessment tool (external (four items) and internal (six items) validity) specifically designed for population-based prevalence studies. Furthermore, a summary assessment evaluates the overall risk of study bias based on the 10 items. A summary assessment deeming a study to be at low risk of bias suggests that ‘further research is very unlikely to change our confidence in the estimate’. A moderate risk of bias rating suggests that ‘further research is likely to have an important impact on our confidence in the estimate and may change the estimate’. The limitations of studies considered to be at high risk of bias suggest that ‘further research is very likely to have an important impact on our confidence in the estimate and is likely to change the estimate’. For this review, a study was considered to have a high risk of bias if the target population was not closely representative of the national population, if there was no use of random selection and if the study had a more than a minimal risk of non-response bias.

Data extraction and synthesis

Two authors (KJ and SB) independently reviewed abstracts for possible inclusion. In cases of non-consensus, an additional independent review was obtained from a third author (VF). Any ongoing discrepancies were resolved via discussion. In cases of incomprehensive study methodology, authors were approached to determine a study’s potential inclusion. Where possible, copies of full articles were obtained for studies meeting the inclusion criteria.

Reviewers extracted standard information per study on study characteristics, target population, research design and verification of poliovirus infection. Only those studies considered to be at low to moderate risk of bias were included in the calculation of prevalence estimates. An average prevalence of poliomyelitis is reported for each study as the number of cases per 100 000 people of all ages or a particular age range, depending on the data available. Rates were checked for accuracy where possible, depending on the data provided. Due to a lack of availability of standardised rates, prevalence rates are reported as crude estimate (ie, unadjusted rates). Studies reporting adjusted values only have not been included in the average prevalence calculation. In instances where a range of prevalence rates have been reported in a study and no overall rate reported (eg, across ethnic groups or different geographical regions or years), we have used the average of this range for the purposes of calculating an overall average prevalence. The research protocol was not subject to ethical approval as no such approval was required according to local regulations.

RESULTS

 Included studies

Figure 1 presents an overview of the study selection process. The initial search yielded 1239 citations. Following scanning of the titles for appropriateness for inclusion, those not meeting criteria and duplicate citations were removed (973). Where available, the abstracts of the remaining 266 potentially relevant titles identified across all sources (EBSCO n=25; ProQuest n=17; Scopus n=88; Web of Science n=136) were obtained. Following the availability and review of 206 abstracts, 114 full articles were independently evaluated for inclusion by two reviewers (SB and KJ). This process led to the elimination of 83 studies that did not meet the required inclusion
Figure 1 Flow diagram of included/excluded studies.

criteria. The remaining 31 articles met inclusion criteria and were included in the review.

The 31 eligible population-based studies reported data from 14 different countries. Data on polio prevalence in low-income to lower middle-income countries were reported in 28 (90%) studies in 11 countries: India (14 studies); Nigeria (2 studies); Ethiopia (4 studies) and one study in each of the following locations: Indonesia, Ghana, Bangladesh, Niger, Cameroon, Sudan, Yemen and Papau New Guinea. Population-based data on polio prevalence in upper-middle to high-income countries were available from three studies in three countries: Japan, Sweden and Brazil.

Study characteristics

Table 1 provides a summary of the characteristics of those articles included in the review, including details of polio verification, population status, study design and risk of bias. The included studies reported on polio prevalence data collected between 1974 and 2004. In terms of methodologies implemented across the included studies, poliovirus infection was verified in 28 (90%) cases via the use of clinical investigations (ie, examination by a physician or similar). Two of these studies also used laboratory investigations (ie, virological confirmation) to confirm a history of polio. Twenty-nine (94%) studies presented data collected by lameness surveys. These included surveys of schools (5), villages (1), families (1), house-to-house surveys (16), or a mixture thereof (4), and postal questionnaires (1). One lameness survey examined a national population. The remaining two studies (6%) used multiple sources of case ascertainment. Studies most commonly examined urban/rural or semirural populations (12), with eight studies limited to rural populations. Only one study reported a specific focus on an urban population. Of the 31 studies included, 26 (84%) presented data based on children and young persons aged <20 years. In terms of risk of bias, the majority of studies (77%) were at moderate (14 studies, 45%) to high (10 studies, 32%) risk of bias (figure 2). Seven studies (23%) were considered to be at low risk of bias.

Poliomyelitis prevalence

In the general population, crude average prevalence across all included studies ranged from 15 per 100 000 in Nigeria to 1733 in Ajmer City, India (figure 3). Among all low-income to lower middle-income countries, crude rates of poliomyelitis prevalence ranged from 15 per 100 000 (Igbo-Ora, Nigeria) to 1733 per 100 000 (Ajmer City, Rajasthan, India). Among all high-income counties, crude rates of poliomyelitis prevalence ranged from 24 (PPS) per 100 000 (Japan) to 380 per 100 000 (Brazil). For those studies considered to be at low to moderate risk of bias, prevalence estimates ranged from 92 in Sweden to 730 in Ethiopia. The total combined prevalence of poliomyelitis for those studies at low to moderate risk of bias ranged from 165 (high-income countries) to 425 (low-income to lower middle-income countries) per 100 000 person-years. The estimated average crude worldwide prevalence is 295 per 100 000 person-years.
Table 1 Details of included population-based studies in reverse chronological order

<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Country (region)</th>
<th>Population status</th>
<th>Population base</th>
<th>Study design/date</th>
<th>Full article</th>
<th>Verification of diagnosis</th>
<th>Risk rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takemura</td>
<td>2004</td>
<td>Japan (Kitakyushu)</td>
<td>Registry of 13000 physically disabled persons</td>
<td>342</td>
<td>Lameness survey (postal questionnaire)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Tessema</td>
<td>2001</td>
<td>Ethiopia (Gondar Zuria district)</td>
<td>General population (urban/rural)</td>
<td>12'000 children aged 1–15 years</td>
<td>Lameness survey (house-to-house)</td>
<td>July-August 1993</td>
<td>Yes</td>
<td>Low</td>
</tr>
<tr>
<td>Anand</td>
<td>1998</td>
<td>India (Ballabgarh, Haryana)</td>
<td>General population (rural)</td>
<td>28'464 children aged &lt;15 years</td>
<td>Lameness survey (house-to-house)</td>
<td>December 1996</td>
<td>Yes</td>
<td>High</td>
</tr>
<tr>
<td>Srinivasa</td>
<td>1997</td>
<td>India (Pondicherry)</td>
<td>General population (urban/rural)</td>
<td>Approx. 11'000 children aged &lt;60 months</td>
<td>Lameness survey (house-to-house)</td>
<td>January–February of each year between 1989 and 1991</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Ahlström</td>
<td>1993</td>
<td>Sweden (Orebro)</td>
<td>General population (urban/rural)</td>
<td>289'341</td>
<td>Multiple sources (hospital, outpatient, institutional, insurance, medical records)</td>
<td>Yes</td>
<td>Search of clinical records</td>
<td>Low</td>
</tr>
<tr>
<td>Soudarssanane</td>
<td>1993</td>
<td>India (Pondicherry)</td>
<td>General population</td>
<td>47'960 children aged 0-6 years</td>
<td>Lameness survey (house-to-house)</td>
<td>April–July 1999</td>
<td>Yes</td>
<td>Low</td>
</tr>
<tr>
<td>Kumar</td>
<td>1991</td>
<td>India (Ambala, Haryana State)</td>
<td>General population</td>
<td>15'761 children aged &lt;15 years</td>
<td>Lameness survey (house-to-house)</td>
<td>January 1989</td>
<td>Yes</td>
<td>High</td>
</tr>
<tr>
<td>Balraj</td>
<td>1990</td>
<td>India (Northern Arcot District, Tamil Nadu State)</td>
<td>General population (rural)</td>
<td>42'045 children aged &lt;5 years</td>
<td>Lameness survey (house-to-house)</td>
<td>February–October 1988</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Mehra</td>
<td>1990</td>
<td>India (New Delhi)</td>
<td>General population (urban/rural)</td>
<td>73'18 children aged 5-15 years</td>
<td>Lameness survey (house-to-house)</td>
<td>June–August 1986</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Parakoyi</td>
<td>1990</td>
<td>Nigeria (Ilorin, Kwara State)</td>
<td>General population (urban/rural)</td>
<td>45'76 children aged 5-9 years</td>
<td>Lameness survey (house-to-house)</td>
<td>March 1988</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Tekle-Haimanot</td>
<td>1990</td>
<td>Ethiopia (Meskan and Moreno subdistricts)</td>
<td>General population (rural)</td>
<td>60'820 adults</td>
<td>Lameness survey (house-to-house)</td>
<td>1986–1988</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Khajuria</td>
<td>1989</td>
<td>India (Haryana)</td>
<td>General population (rural)</td>
<td>37'851 children aged 1-11 years</td>
<td>Lameness survey (village)</td>
<td>1985</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Dekker</td>
<td>1988</td>
<td>Ethiopia (Addis Ababa)</td>
<td>General population</td>
<td>256'092 children aged &lt;20 years</td>
<td>Lameness survey (school)</td>
<td>Unknown date</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Maru</td>
<td>1988</td>
<td>Ethiopia (Gondar)</td>
<td>General population (urban/rural)</td>
<td>17'941 children aged 5-8 years</td>
<td>Lameness survey (house-to-house)</td>
<td>February–July 1983</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Osuntokun</td>
<td>1987</td>
<td>Nigeria (Igbo-Ora)</td>
<td>General population</td>
<td>18'954</td>
<td>Lameness survey (house-to-house)</td>
<td>Unknown date</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Tidke</td>
<td>1986</td>
<td>India (Bombay)</td>
<td>General population (slums)</td>
<td>15'165 children aged &lt;6 years</td>
<td>Lameness survey (house-to-house)</td>
<td>Unknown date</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Broca</td>
<td>1985</td>
<td>India (Amner City, Rajasthan)</td>
<td>General population</td>
<td>60'00 children aged 5-15 years</td>
<td>Lameness survey (house-to-house)</td>
<td>August 1981–March 1982</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
<tr>
<td>Basu</td>
<td>1984</td>
<td>India (National)*</td>
<td>General population (urban/rural)</td>
<td>715'039 children aged 5-9 years</td>
<td>Lameness survey (national)</td>
<td>1981–1982</td>
<td>Yes</td>
<td>Clinical investigation</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Country (region)</th>
<th>Population status</th>
<th>Population base</th>
<th>Study design/date</th>
<th>Full article</th>
<th>Verification of diagnosis</th>
<th>Risk rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heymann</td>
<td>1983</td>
<td>Rep. of Cameroon*</td>
<td>General population</td>
<td>3710 children aged 5–11</td>
<td>Multiple sources (hospital and clinical registers, house-to-house and school lameness survey)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Olive</td>
<td>1984</td>
<td>Sudan* (Port Sudan and Juba, Khartoum)</td>
<td>General population (urban/semirural)</td>
<td>40499 children aged 5–13</td>
<td>Lameness survey (school)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Sriratha</td>
<td>1984</td>
<td>South India* (North Arcot District, Tamil Nadu)</td>
<td>General population (rural)</td>
<td>14643 children aged 5–17</td>
<td>Lameness survey (school)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>High</td>
</tr>
<tr>
<td>Hajaz</td>
<td>1983</td>
<td>Yemen Arab Republic*</td>
<td>General population (rural)</td>
<td>12443 children aged 5–13</td>
<td>Lameness survey (school) and community</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Low</td>
</tr>
<tr>
<td>Sabin</td>
<td>1983</td>
<td>Brazil (Federal District of Brazil)</td>
<td>General population</td>
<td>20807 children aged 6–7 and 10–11</td>
<td>Lameness survey (school)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hall</td>
<td>1982</td>
<td>Papua New Guinea* (Gulf Province)</td>
<td>General population</td>
<td>3368 children</td>
<td>Lameness survey (school)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>High</td>
</tr>
<tr>
<td>Rottl</td>
<td>1980</td>
<td>South India* (Pondicherry)</td>
<td>General population (urban)</td>
<td>6683 children aged 6–15</td>
<td>Lameness survey (house-to-house and school)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Thuriaux</td>
<td>1982</td>
<td>Niger* (N’amey, Kaffo, Tillaberry, Gotheye)</td>
<td>General population (rural/urban)</td>
<td>46772 children aged 5–14</td>
<td>Lower limb motor disorders survey (school)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Snyder</td>
<td>1981</td>
<td>Bangladesh* (Dhaka)</td>
<td>General population (rural)</td>
<td>25000 children aged 5–14</td>
<td>Lameness survey (house-to-house)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
<tr>
<td>Ulfah</td>
<td>1981</td>
<td>Indonesia* (Yogyakarta)</td>
<td>Philanthropic private agency</td>
<td>94376 children and adolescents aged &lt;20</td>
<td>Lameness survey (families)</td>
<td>Yes</td>
<td>Clinical and laboratory investigation</td>
<td>High</td>
</tr>
<tr>
<td>Jhala</td>
<td>1979</td>
<td>India* (Patan Taluka, Gujarat)</td>
<td>General population (rural)</td>
<td>57435 adults</td>
<td>Lameness survey (house-to-house)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>High</td>
</tr>
<tr>
<td>Nicholas</td>
<td>1977</td>
<td>Ghana* (Dambia)</td>
<td>General population (rural)</td>
<td>13232 children aged 0–15</td>
<td>Lameness survey (school, village)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>High</td>
</tr>
<tr>
<td>Hardas</td>
<td>1974</td>
<td>India* (Nagpur)</td>
<td>General population (urban/semirural)</td>
<td>36826 children aged 0–12</td>
<td>Lameness survey (house-to-house)</td>
<td>Yes</td>
<td>Clinical investigation</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

*Low-income to lower-middle income countries.
†Based on 18 studies with low to moderate risk of bias.
‡Based on three studies with low to moderate risk of bias.

| Low-income to lower middle-income countries: average prevalence | 425 |
| Upper-middle to high-income countries: average prevalence | 165 |
| International: total average prevalence | 295 |
This study reviews all the available data from population-based poliomyelitis prevalence studies. Findings reveal significant discrepancies in average crude unadjusted prevalence rates, both between and within countries. Across all included studies and within low-income to lower middle-income countries, prevalence rates ranged from 15 per 100,000 person-years in Igbo-Ora, Nigeria to 1733 in Ajmer City, India. Within high-income countries, rates ranged from 24 in Japan to 380 in Brazil. Worldwide variations in prevalence ratings could be attributed to the diversity (and at times a lack of clarity) of applied case definitions and assessment processes to determine a history of poliomyelitis. For example, while the majority of studies used lameness surveys, some studies were limited to the examination of lower extremity disabilities. Other studies included the examination of upper extremity disabilities in their efforts to identify those affected by poliovirus leading to poliomyelitis. Three studies were limited to the examination of PPS.
only. Such inconsistencies are of concern given incomplete case ascertainment or disease misclassification can significantly skew the reported prevalence. Even assuming that all cases were ascertained in a given study, data would still omit those survivors of poliomyelitis who are now free from any observable, physical ailments. However, perhaps more problematic are the risks for over-reporting due to the inclusion of cases of non-polio AFP.

Alongside methodological variations and shortcomings discussed above, rather than informing estimates of the prevalence of survivors of poliomyelitis worldwide, limitations in the literature render this review largely of the historical prevalence of residual AFP that may be due to poliomyelitis. AFP is a clinical syndrome with a broad array of possible etiologies (ie, spinal cord compression, trauma, exposure to chemicals and recent illness) that serves as a proxy for poliomyelitis.10 Figures from AFP surveillance surveys, an essential strategy of the Global Polio Eradication Initiative, suggest that non-polio AFP affects one to three cases per 100,000 children aged <15 years per year.11 Subsequently lameness surveys, most common in this review, risk overstating the prevalence of survivors of poliomyelitis. Such risks are especially high in areas such as Afghanistan, India and Nigeria who have the highest annualised non-polio AFP rate compared with the number of poliovirus cases.12 Furthermore, few studies examined the prevalence of survivors of poliomyelitis across all age groups, nor included samples that were representative of the respective national population being studied to inform appropriate gender, age and ethnicity estimates. Findings from lameness surveys in the current review also had considerable variation in the range of age groups surveyed (ie, 5–15 years, 0–6 years).

Our findings suggest the average crude worldwide prevalence of 295/100,000 person-years. However, many of the studies included in this review were undertaken in geographical areas where rates of non-polio AFP are high. Alongside the dated nature of studies (many being published more than 30 years ago), since ageing population, and a 99% reduction in the more recent incidence of poliovirus infection, it must be noted that the actual worldwide prevalence is likely much lower.

This review has provided an overview of studies to date that have endeavoured to examine the prevalence of survivors of poliomyelitis. While all efforts were made to identify and access all articles relevant to the review, it is important to acknowledge the likelihood that some studies (ie, unpublished or inaccessible studies) were not identified by the search strategy and therefore excluded. Well-designed epidemiological studies are clearly required to accurately determine the current prevalence of poliomyelitis survivors, living either with or without AFP.

Future epidemiological polio studies can reduce bias noted in this review by including the use of random or cluster sampling, the examination of populations that are representative of the national population where possible and the application of clear case definitions and diagnosis. In addition to recommending that future studies adhere to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement,13 we offer specific recommendations for the pursuit of future studies examining prevalence of survivors of poliomyelitis in box 1.

Conclusions

In conclusion, this review reported prevalence of poliomyelitis survivors worldwide from all identified studies. The majority of research to date has been limited to the examination of children and adolescents in low-income to lower middle-income countries (predominantly India) who reside in geographical regions that are not representative of the national population (eg, in terms of age, sex,
ethnic distributions) and face high rates of non-polio AFP. Further research of the prevalence of survivors of poliomyelitis is required using a population-based approach, examining nationally representative samples of all ages, particularly in high-income countries including those declared to be polio free. Such efforts will reduce risks for sampling and measurement bias and improve capacity to provide reliable and more robust worldwide prevalence estimates.

Contributors GJ conceived the study. SB conducted searches and extracted the data. KJ and SB compiled and analysed data. VLF, AT and GJ advised throughout the study. KJ prepared the initial draft of the manuscript. All authors provided conceptual input and critical review of drafts.

Funding This work was funded by The Sir Thomas and Lady Duncan Trust Fund

Competing interests None declared.

Patient consent This submission is a systematic literature review of published data.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies

Kelly M Jones, Shivanthi Balalla, Alice Theadom, Gordon Jackman and Valery L Feigin

BMJ Open 2017 7:
doi: 10.1136/bmjopen-2016-015470

Updated information and services can be found at:
http://bmjopen.bmj.com/content/7/7/e015470

These include:

References
This article cites 39 articles, 10 of which you can access for free at:
http://bmjopen.bmj.com/content/7/7/e015470#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Epidemiology (2074)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/